Pharmaceutical industry
On this page, you will find information on the Agency’s activities that are most relevant to pharmaceutical industry, including news, and events.
You can contribute to EMA's work by responding to our public consultations.
Learn more about how the pharmaceutical industry is actively involved in EMA's work.
Featured information for the pharmaceutical industry
EMA workshop on antivirals and monoclonal antibodies for COVID-19 and influenza: registration open
EMA invites academia, regulatory, pharmaceutical industry and healthcare professional stakeholders to register for our workshop on primary efficacy endpoints for antivirals and monoclonal antibodies intended to treat COVID-19 and influenza. The workshop will take place on 5 and 6 June 2025, only remotely. EMA will broadcast the workshop live.
Reflection paper on linking to electronic product information (ePI) from EU medicine packages: public consultation
A draft reflection paper detailing how to make electronic product information (ePI) easily accessible for patients, consumers, and healthcare professionals across the European Union is available for public consultation. The document describes how to access the ePI by scanning a code printed on the medicine package. The public consultation is open until 30 June 2025.
Process changes for centrally authorised generic, hybrid or biosimilar reference medicines
As of April 2025, EMA will no longer send notifications to marketing authorisation holders (MAHs) of centrally authorised generics, hybrids or biosimilars of centrally authorised reference medicines when its product information has been updated. Instead, EMA will start publishing this product information as Word documents with visible track changes, in addition to clean PDFs. These documents will be available in all EU languages on medicine pages on this website. MAHs will need to download these documents to submit the relevant type IB variation within two months. More information is available in section 4.2 on the Generic and hybrid applications webpage.
Medical devices and in vitro diagnostics: Update on compliance with requirements for class I integral medical devices
EMA has updated its guidance (‘questions and answers’) on the implementation of EU regulations on medical devices and in vitro diagnostic medical devices. This addresses situations when a declaration of conformity is not available for class I integral medical devices (excluding Is – sterile condition and Im – measuring function devices). When this happens, marketing authorisation holders can submit a statement of compliance with the relevant general safety and performance requirements (GSPRs) to meet requirements of article 117 of the Medical Device Regulation.
EMA launches full version of European Shortages Monitoring Platform (ESMP)
As of 29 January 2025, marketing authorisation holders (MAHs) and national competent authorities (NCAs) can now also use this platform to submit data on supply and demand of medicines during crisis and preparedness situations. This launch is ahead of the legal deadline of 2 February 2025. In November 2024, EMA released the first functionality of the platform for MAHs to report shortages of centrally authorised products. More information is available on this website, including training materials and recordings of previous training events.
Transition of post-authorisation procedures to IRIS: actions for marketing authorisation holders
As of January 2025, all submissions for EMA-led post-authorisation procedures initiated from 20 December 2024 via the current systems will be managed in the IRIS online platform. This concerns all centrally and nationally authorised products. Marketing authorisation holders for these procedures should have an EMA account and industry user role. Periodic safety update report procedures will transition to IRIS from 6 February 2025. More information is available in EMA’s submission guidance on regulatory procedure management for the product lifecycle management.
New procedural guidance on the amended Variations Regulation
Guidance on the implementation of the amended Variations Regulation is available for marketing authorisation holders of human medicines. The Regulation will be applicable as of 1 January 2025. It includes new and updated processes on the mandatory annual update for Type IA variations and its exemptions, on the (super-) grouping of Type IA variations, on the mandatory and voluntary worksharing procedure and on recommendation for unforeseen variations.
EMA publishes reflection paper on use of artificial intelligence (AI)
This reflection paper provides considerations for medicine developers and applicants on the safe and effective use of AI and machine learning throughout the medicine lifecycle. The document covers stages from medicine development to the post-authorisation. CHMP and CVMP adopted this reflection paper in September 2024.
Latest news
Ten new medicines recommended for approval; another four medicines recommended for extension of their therapeutic indications
Third CAR T-cell therapy for high-mortality cancer
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting
Updated vaccines will help maintain protection against disease as virus continues to evolve
Publications of interest
EMA's 2023 annual report
Navigate through the digital report to view interviews, short videos and an interactive timeline of the Agency’s main activities in 2023. Read the traditional PDF version to see additional figures and statistics on EMA's regulatory procedures and activities.
Factsheet: PRIME – Paving the way for promising medicines for patients
Check our factsheet for an at-a-glance overview of EMA's PRIME scheme.
Video: Working for every patient in Europe
Watch our short video for a quick and easy explanation of who EMA is and what it does. (video in English, with subtitles in 24 different languages).